fda compounding semaglutide warning 2025 october New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Medscape | The FDA has
Description
Of note, the overall incidence of small bowel obstruction was low (1.4%), and no case was reported in the semaglutide group
Metabolic-bariatric surgery reduces pancreatic cancer risk: a meta-analysis of over 3.7 million adults, independent of type 2 diabetes status
Clinically, they may: improve adherence lower system cost reduce injection fatigue expand treatment reach But pills wont replace the fundamentals either
Not because these are superior foods, but because they are gentle on a slow-moving gut
Now, gently swirl the vial in a slow, circular motion
